Good morning, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? While you ponder the possibilities, we will celebrate yet another gorgeous morning with some needed cups of stimulation. What better way to enjoy a cool breeze and sparkling sun? And of course, we are happy to pass along the latest menu of tidbits to get you started on your way. Hope you have a smashing day and do stay in touch. We accept documents and tips. …

Purdue Pharma and lawyers for cities, counties, and states across the country are negotiating a multibillion-dollar settlement that would resolve about 2,000 lawsuits against the company, which would declare bankruptcy as part of the deal, the Washington Post writes. The Sackler family, which owns Purdue, would lose control of the business and contribute at least $3 billion in personal funds to the settlement, which could total as much as $12 billion. A “public beneficiary trust” would be created to direct profit from drug sales to the plaintiffs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy